| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
Trial completed |
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
Enrollment reduced: 200 -> 50 participants |
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
date change Primary completion moved earlier: 2026-05-30 -> 2025-09-18 |
| 2026-06-12 | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive… |
date change Completion moved earlier: 2026-05-30 -> 2025-09-18 |
| 2026-06-09 | NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions |
Primary endpoint(s) modified |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05160922 | Crizotinib Continuation Clinical Study | NSCLC | Active, Not Recruiting |
| Phase 3 | |||
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally… | Non Small Cell Lung Cancer | Recruiting |
| NCT02838420 | A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib… | Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT04603807 | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants… | Carcinoma, Non-Small-Cell Lung | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic… | Metastatic Uveal Melanoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Lymphoma, Non-Hodgkin | Recruiting |
| NCT06563999 | Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare… | Lung Cancer Stage III | Recruiting |
| NCT06357975 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes… | Advanced Lymphoma | Active, Not Recruiting |
| NCT04439253 | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes… | Advanced Lymphoma | Active, Not Recruiting |
| NCT04439266 | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes… | Advanced Lymphoma | Active, Not Recruiting |
| NCT06360575 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion… | Advanced Lymphoma | Active, Not Recruiting |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… | Advanced Lymphoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Metastatic Uveal Melanoma | Recruiting |
| Phase 1 | |||
| NCT04693468 | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or… | Advanced Malignant Solid Neoplasm | Recruiting |
| Not specified | |||
| NCT03375242 | Safety and Efficacy of Xalkori ROS1 | Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That… | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Active, Not Recruiting |